Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting factors.

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The FDA granted approval to Sanofi’s fitusiran for the prophylactic treatment of people with hemophilia A or B with or without inhibitors. Fitusiran, which will be marketed by the name of ...

The FDA granted approval to Sanofi’s fitusiran for the prophylactic treatment of people with hemophilia A or B with or without inhibitors. Fitusiran, which will be marketed by the name of ...

Get Instant Summarized Text (Gist) The FDA has approved Qfitlia (fitusiran) for reducing bleeding episodes in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia ...

WEDNESDAY, April 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia offers less frequent administration ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.